Article Sidebar
Published:
Sep 6, 2024Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Effect of the combination of radioiodine therapy and euthyrox in BRAF-mutated thyroid cancer post-total thyroidectomy
Abstract
Purpose: To investigate the effect of combining radioiodine therapy with euthyrox in treating thyroid cancer with BRAF gene mutation following total thyroidectomy (TT).
Methods: This retrospective study analyzed records of 98 differentiated thyroid cancer (TC) patients with BRAF gene mutation who underwent TT between February 2018 and January 2020 at Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, China. The patients were randomized into control (46 patients) and study groups (53 patients). Control group received euthyrox, while the study group received euthyrox in addition to radioiodine following total thyroidectomy. Efficacy, thyroid function before and after treatment, incidence of adverse reactions, and 3-year recurrence rates were evaluated.
Results: The study group showed significantly higher overall response rate (ORR) compared to control group (p < 0.05). There were no significant differences in thyrotropin (TSH), free thyroxine (FT4), and free triiodothyronine (FT3) levels between the groups before treatment (p > 0.05). After treatment, both groups exhibited significant changes in thyroid function, with decreased TSH, and increased FT4 and FT3 levels (p < 0.05). Post-treatment TSH levels were significantly lower while FT4 and FT3 levels were significantly higher in the study group compared to control group (p < 0.05).
Conclusion: Combining radioiodine therapy and Euthyrox following total thyroidectomy enhances therapeutic outcomes in patients with BRAF-mutated TC, improves thyroid function and reduces recurrent risk without increasing adverse reactions. Further studies will aim to expand the sample size and stratify patients by severity to comprehensively validate these findings
